Finasteride Powder CAS 98319-26-7

CAS:98319-26-7

MF: C23H36N2O2

MW:372.54

EINECS:620-534-3

Specification: 99% min Vitamin E Acetate

Sample:Finasteride Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance:white to beige

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Finasteride Usage and Synthesis.

Finasteride is a 4-azasteroid compound that is a specific inhibitor of the intracellular enzyme, type II 5a-reductase, in the metabolism of testosterone to the more potent dihydrotestosterone.

And benign prostatic hyperplasia or called prostatic hypertrophy depends on the conversion of testosterone to dihydrotestosterone in the prostate.

This drug is very effective in reducing dihydrotestosterone in the blood and prostate. Finasteride has no affinity for the androgen receptor.

Finasteride is a 5 alpha reductase inhibitor, which works through its hormonal mechanism of action, i.e., by inhibiting the conversion of testosterone to dihydrotestosterone (DHT), which results in a reduction in the size of the prostate gland to improve symptoms, increase the rate of urinary flow, and prevent the progression of benign prostatic hyperplasia (BPH).

Uses and functions of Finasteride.

For the treatment of enlarged prostate and baldness in men.

Finasteride is a 4-azasteroid compound that is a specific inhibitor of the intracellular enzyme, type II 5a-reductase, in the metabolism of testosterone to the more potent dihydrotestosterone. And benign prostatic hyperplasia or called prostatic hypertrophy depends on the conversion of testosterone to dihydrotestosterone in the prostate. This drug is very effective in reducing dihydrotestosterone in the blood and prostate. Finasteride has no affinity for the androgen receptor.

Pharmacological Effect of Finasteride.

It is a 4-azosteroid hormone compound, a specific type II 5α-reductase competitive inhibitor, inhibits the conversion of peripheral testosterone to dihydrotestosterone, and reduces the levels of dihydrotestosterone in the blood and tissues of the prostate and skin. The growth and development of prostate and benign hyperplasia are dependent on dihydrotestosterone. Finasteride inhibits prostate hyperplasia and improves clinical symptoms associated with BPH by lowering the levels of dihydrotestosterone in the blood and prostate tissues.

Drug interactions of Bulk Finasteride.

1. Finasteride has no significant effect on the cytochrome P450-associated drug-metabolising enzyme system. Compounds that have been tested in men include propranolol, digoxin, glibenclamide, warfarin, theophylline, and antipyrine, none of which have been found to have clinically meaningful interactions with finasteride.

2, Other combination therapies. Although no specific drug-drug interaction studies have been performed, in clinical studies finasteride has been used in combination with angiotensin-converting enzyme inhibitors, acetaminophen, acetylsalicylic acid, α-blockers, β-blockers, calcium channel blockers, nitrate esters for cardiac use, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), quinolones, and benzodiazepines. No clinically significant adverse interactions were observed when azepines were used concomitantly.